Markets:

Overview

News

Currencies

International

Treasuries

Revolution Medicines, Inc. - Common Stock (NQ:RVMD)

152.54 +5.53 (+3.76%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Revolution Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Revolution Medicines (RVMD): The New Titan of the RAS Pathway (2026 Research Feature)

April 15, 2026

As of April 15, 2026, the biotechnology sector is witnessing a paradigm shift in precision oncology, spearheaded by Revolution Medicines, Inc. (Nasdaq: RVMD). Once considered a high-risk clinical-stage...

Via Finterra

Topics Initial Public Offering

The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report)

April 14, 2026

As of today, April 14, 2026, the biotechnology landscape is being reshaped by a singular clinical milestone that many once deemed impossible. Just twenty-four hours ago, Revolution Medicines, Inc....

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

Revolution Medicines Inc (NASDAQ:RVMD) Reports Q4 2025 Earnings Miss, Reaffirms Key Phase 3 Timeline ↗

February 25, 2026

Via Chartmill

Topics Earnings

Which stocks are moving on Monday? ↗

April 13, 2026

Here are the top movers in Monday's session, showcasing the stocks with significant price changes.

Via Chartmill

What's going on in today's session ↗

April 13, 2026

Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

These stocks are gapping in today's session ↗

April 13, 2026

Let's have a look at what is happening on the US markets on Monday. Below you can find the gap up and gap down stocks in today's session.

Via Chartmill

Which stocks are moving before the opening bell on Monday? ↗

April 13, 2026

Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer

April 13, 2026

From Revolution Medicines, Inc.

Via GlobeNewswire

Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? ↗

March 22, 2026

Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead program advancing in clinical trials for breast cancer.

Via The Motley Fool

This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset ↗

March 21, 2026

This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.

Via The Motley Fool

Topics Regulatory Compliance

This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth ↗

March 21, 2026

This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.

Via The Motley Fool

Topics Regulatory Compliance

This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash ↗

March 21, 2026

Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.

Via The Motley Fool

Topics Regulatory Compliance

DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗

March 21, 2026

iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but...

Via The Motley Fool

Topics Derivatives ETFs Regulatory Compliance

This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year ↗

March 20, 2026

This clinical-stage biotech develops therapies for serious immunological diseases, with a focus on late-stage biologic candidates.

Via The Motley Fool

Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗

March 19, 2026

Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships.

Via The Motley Fool

Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗

March 19, 2026

Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline.

Via The Motley Fool

Topics Regulatory Compliance

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? ↗

March 15, 2026

This clinical-stage biotech develops antibody therapies targeting autoimmune diseases, with a lead candidate in Phase II trials.

Via The Motley Fool

Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing ↗

March 09, 2026

This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology.

Via The Motley Fool

Topics Regulatory Compliance

Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing ↗

March 06, 2026

This clinical-stage biotech develops precision oncology therapies and diagnostics targeting unmet needs in breast and ovarian cancer.

Via The Motley Fool

Topics Regulatory Compliance

Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing ↗

March 05, 2026

This clinical-stage biotech develops small-molecule therapies for liver and metabolic diseases, targeting unmet needs in NASH and obesity.

Via The Motley Fool

Topics Regulatory Compliance

Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing ↗

March 04, 2026

This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated oncology pipeline.

Via The Motley Fool

Topics Regulatory Compliance

Relay Therapeutics Stock Up 235% This Past Year as One Fund Lifts Bet to $110 Million ↗

February 27, 2026

Relay Therapeutics develops precision medicines targeting oncology and genetic diseases, leveraging proprietary computational technology.

Via The Motley Fool

Topics Regulatory Compliance

Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million ↗

February 27, 2026

This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.

Via The Motley Fool

Topics Regulatory Compliance

Revolution Medicines (RVMD) Earnings Transcript ↗

February 25, 2026

Revolution Medicines (RVMD) Earnings Transcript

Via The Motley Fool

Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position ↗

February 25, 2026

Structure Therapeutics develops oral drugs for chronic diseases, with lead assets targeting diabetes, obesity, and cardiovascular care.

Via The Motley Fool

Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit ↗

February 25, 2026

This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of clinical-stage candidates.

Via The Motley Fool

Topics Regulatory Compliance

Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction ↗

February 25, 2026

Disc Medicine develops therapies for rare blood disorders, leveraging clinical-stage biotech expertise in red blood cell biology.

Via The Motley Fool

Topics Regulatory Compliance

Marc Andreessen’s a16z Invests $465 Million in Navan’s Corporate Spending Platform, According to Recent SEC Filing ↗

February 18, 2026

a16z Capital Management, the venture firm founded by Marc Andreessen and Ben Horowitz, committed $465 million to Navan, backing its expansion from corporate travel booking into integrated enterprise...

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗

February 17, 2026

Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.

Via The Motley Fool

Topics Regulatory Compliance

Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗

February 17, 2026

This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.

Via The Motley Fool

Topics Regulatory Compliance

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.